Vaxcyte, Inc. $PCVX Shares Sold by Seven Fleet Capital Management LP

Seven Fleet Capital Management LP cut its position in Vaxcyte, Inc. (NASDAQ:PCVX) by 76.8% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 29,800 shares of the company’s stock after selling 98,650 shares during the quarter. Seven Fleet Capital Management LP’s holdings in Vaxcyte were worth $1,778,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Corient Private Wealth LP bought a new position in Vaxcyte in the 2nd quarter worth about $2,141,000. Bank of America Corp DE bought a new stake in shares of Vaxcyte during the second quarter valued at approximately $62,711,000. Odyssean LLC boosted its position in shares of Vaxcyte by 211.5% during the second quarter. Odyssean LLC now owns 62,638 shares of the company’s stock worth $3,641,000 after buying an additional 42,527 shares during the period. Man Group plc acquired a new position in shares of Vaxcyte during the second quarter worth approximately $4,745,000. Finally, Jupiter Topco LLC acquired a new position in shares of Vaxcyte during the second quarter worth approximately $1,044,355,000. 96.78% of the stock is owned by institutional investors and hedge funds.

Vaxcyte Trading Down 0.0%

PCVX stock opened at $61.16 on Friday. Vaxcyte, Inc. has a 52 week low of $30.81 and a 52 week high of $65.00. The company has a market capitalization of $9.10 billion, a price-to-earnings ratio of -8.02 and a beta of 1.22. The firm’s 50-day moving average is $58.22 and its two-hundred day moving average is $56.20.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($1.97) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.06) by $0.09. During the same quarter in the prior year, the firm earned ($1.22) earnings per share. On average, equities research analysts predict that Vaxcyte, Inc. will post -7.6 earnings per share for the current year.

Insider Transactions at Vaxcyte

In other news, insider Harpreet S. Dhaliwal sold 17,000 shares of Vaxcyte stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $55.00, for a total transaction of $935,000.00. Following the transaction, the insider directly owned 76,756 shares in the company, valued at approximately $4,221,580. This trade represents a 18.13% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Grant Pickering sold 2,000 shares of the business’s stock in a transaction on Monday, July 27th. The stock was sold at an average price of $55.65, for a total value of $111,300.00. Following the completion of the sale, the chief executive officer directly owned 133,215 shares in the company, valued at $7,413,414.75. This represents a 1.48% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 121,873 shares of company stock valued at $6,671,730. 3.30% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research firms recently commented on PCVX. Zacks Research upgraded Vaxcyte from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 12th. Wall Street Zen upgraded Vaxcyte from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 8th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Vaxcyte in a research report on Monday, July 6th. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $86.00.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.